Trial Profile
Effect of anaplerotic treatment on brain energy profile evolution in early stage of the Huntington disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2016
Price :
$35
*
At a glance
- Drugs Triheptanoin (Primary)
- Indications Huntington's disease
- Focus Pharmacodynamics; Proof of concept
- Acronyms TRIHEP2
- 07 Jan 2015 According to an Ultragenyx Pharmaceutical media release, results were published in the online issue of Neurology in 2015.
- 12 Aug 2013 New trial record
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.